| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Thakkar Roopal | EVP, R&D and CSO | 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO | /s/ T.O. Odutayo, Attorney-in-Fact for Roopal Thakkar | 20 Feb 2026 | 0002004979 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ABBV | Common Stock, $0.01 par value | Award | $0 | +6,015 | +14% | $0.000000 | 48,291 | 18 Feb 2026 | Direct | F1 |
| transaction | ABBV | Common Stock, $0.01 par value | Award | $0 | +2,138 | +4.4% | $0.000000 | 50,429 | 18 Feb 2026 | Direct | F2 |
| transaction | ABBV | Common Stock, $0.01 par value | Award | $0 | +3,346 | +6.6% | $0.000000 | 53,775 | 18 Feb 2026 | Direct | F3 |
| transaction | ABBV | Common Stock, $0.01 par value | Award | $0 | +6,638 | +12% | $0.000000 | 60,413 | 18 Feb 2026 | Direct | F4 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ABBV | Option (Right to buy) | Award | $0 | +21,937 | $0.000000 | 21,937 | 18 Feb 2026 | Common Stock | 21,937 | $230.04 | Direct | F5 |
| Id | Content |
|---|---|
| F1 | Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. |
| F2 | Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. |
| F3 | Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. |
| F4 | Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. |
| F5 | Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,313 on February 18, 2027, 7,312 on February 18, 2028, and 7,312 on February 18, 2029. |